Cover Image
Read Now

Drugs for pulmonary arterial hypertension project protocol

CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosent...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health February 2014, 2014
Series:CADTH therapeutic review report
Subjects:
Canada
Cost-benefit Analysis
Hypertension, Pulmonary / Drug Therapy
Antihypertensive Agents / Therapeutic Use
Review Literature As Topic
Antihypertensive Agents / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but is not yet approved for the treatment of PAH in Canada (riociguat). The clinical and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice delivered by CDEC are provided to CADTH participating jurisdictional drug programs to inform their policy decisions
Physical Description:1 PDF file (ii, 10 pages)

Similar Items